FGFR Agonist Dimeric Compounds for Angiogenesis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies lack effective synthetic molecules that can induce the dimerization of endogenous Fibroblast Growth Factor receptors (FGFRs) to activate angiogenesis, a process crucial for revascularization and tissue repair.
Innovation Solution
Development of new synthetic compounds with a dimeric structure that act as agonists for FGFRs, specifically designed to induce receptor dimerization, thereby activating angiogenesis through a linking group that allows covalent binding of monomeric units, facilitating the activation of FGFRs and subsequent angiogenic processes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If natural compounds or cytokines are used to activate FGFRs, then angiogenesis can be stimulated, but the complexity of the therapy increases and the specificity of action decreases
Solution Approach 1:
The patent segments the complex natural FGF molecules into simplified synthetic monomeric units (indolizine or imidazo[1,5-a]pyridine derivatives) that retain the essential receptor-binding functionality. Each monomer contains a core heterocyclic structure with specific substituent patterns that mimic the critical binding features of natural FGFs, allowing selective FGFR activation without the complexity of full-length cytokines
Solution Approach 2:
The patent systematically varies key molecular parameters of the monomeric units, including the heterocyclic core type (indolizine vs. imidazo[1,5-a]pyridine), substituent positions (R, R1, R2, R3, R4 groups), and linker characteristics to optimize FGFR binding affinity and selectivity. This parameter optimization enables precise control over receptor interaction while maintaining molecular simplicity
2Reliability
If dimeric compounds are designed to induce FGFR dimerization, then agonist activity is enhanced, but the synthesis complexity increases
Solution Approach 1:
The dimeric compounds are constructed from two separate monomeric units connected by a linker group, allowing independent synthesis and characterization of each monomer before assembly. This modular architecture simplifies the overall manufacturing process compared to de novo synthesis of complex dimeric structures, as each component can be optimized and produced separately using established heterocyclic chemistry protocols
Solution Approach 2:
The linker group serves as an intermediary element that connects the two monomeric units while maintaining their individual receptor-binding capabilities. The linker's flexible structure allows proper spatial orientation of the monomers for effective FGFR dimerization induction, and its modular nature facilitates easy modification to optimize pharmacokinetic properties without affecting the core agonist functionality
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds effectively induce angiogenesis, promoting revascularization and tissue repair, as demonstrated by their ability to enhance blood vessel formation and improve conditions in ischemic areas, making them a potential therapeutic choice for various cardiovascular and tissue-related disorders.
Implementation Method 1
inducing the dimerization of FGFs receptors
Implementation Method 2
L represents a linking group which binds M1 and M2 covalently
Implementation Method 3
cell surface receptors with tyrosine kinase activity transmit information across the plasma membrane, in particular by mechanisms of dimerization of the extracellular domains of these receptors
Data Source
AI summary
FGF receptor agonist compounds corresponding to the general formula: M1-L-M2 in which M1 and M2, which may be identical or different, each represent, independently of one another, a monomer unit M, and L represents a linker group which covalently links M1 and M2, wherein said monomer unit corresponds to the general formula M which follows: (I). Preparation process and therapeutic use.